Compare GETY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | GERN |
|---|---|---|
| Founded | 1995 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 753.3M |
| IPO Year | N/A | 1996 |
| Metric | GETY | GERN |
|---|---|---|
| Price | $1.31 | $1.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $5.01 | $3.00 |
| AVG Volume (30 Days) | 1.7M | ★ 7.8M |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $946,327,000.00 | $183,403,000.00 |
| Revenue This Year | $2.53 | $147.42 |
| Revenue Next Year | $3.07 | $37.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.10 | ★ 522.13 |
| 52 Week Low | $1.20 | $1.04 |
| 52 Week High | $3.21 | $3.12 |
| Indicator | GETY | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 49.20 |
| Support Level | $1.26 | $1.28 |
| Resistance Level | $1.34 | $1.48 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 64.10 | 16.92 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.